CL2017000558A1 - Terapia de combinación - Google Patents

Terapia de combinación

Info

Publication number
CL2017000558A1
CL2017000558A1 CL2017000558A CL2017000558A CL2017000558A1 CL 2017000558 A1 CL2017000558 A1 CL 2017000558A1 CL 2017000558 A CL2017000558 A CL 2017000558A CL 2017000558 A CL2017000558 A CL 2017000558A CL 2017000558 A1 CL2017000558 A1 CL 2017000558A1
Authority
CL
Chile
Prior art keywords
combination therapy
effective amount
formula
combination
neurodegenerative
Prior art date
Application number
CL2017000558A
Other languages
English (en)
Inventor
Patrick Cornelious May
Dustin James Mergott
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CL2017000558A1 publication Critical patent/CL2017000558A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Massaging Devices (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

<p>LA PRESENTE INVENCIÓN PROPORCIONA UN MÉTODO PARA TRATAR UNA ENFERMEDAD NEURODEGENERATIVA O COGNITIVA, QUE COMPRENDE ADMINISTRAR A UN PACIENTE QUE NECESITE DICHO TRATAMIENTO UNA CANTIDAD EFICAZ DE UN COMPUESTO DE LA FÓRMULA:</p> <p>O UNA SAL FARMACÉUTICAMENTE ACEPTABLE DE ESTE; EN COMBINACIÓN CON UNA CANTIDAD EFICAZ DE UN ANTICUERPO MONOCLONAL ABETA ANTI-N3PGLU.</p>
CL2017000558A 2014-09-16 2017-03-08 Terapia de combinación CL2017000558A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462050967P 2014-09-16 2014-09-16

Publications (1)

Publication Number Publication Date
CL2017000558A1 true CL2017000558A1 (es) 2017-11-10

Family

ID=54207720

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017000558A CL2017000558A1 (es) 2014-09-16 2017-03-08 Terapia de combinación

Country Status (27)

Country Link
US (1) US9999624B2 (es)
EP (1) EP3193882A1 (es)
JP (1) JP6339741B2 (es)
KR (1) KR101871128B1 (es)
CN (1) CN106687136A (es)
AP (1) AP2017009794A0 (es)
AR (1) AR101740A1 (es)
AU (1) AU2015318257B2 (es)
BR (1) BR112017003571A2 (es)
CA (1) CA2956835A1 (es)
CL (1) CL2017000558A1 (es)
CO (1) CO2017001875A2 (es)
CR (1) CR20170080A (es)
DO (1) DOP2017000071A (es)
EA (1) EA031764B1 (es)
EC (1) ECSP17015977A (es)
IL (1) IL250387A0 (es)
MX (1) MX2017003414A (es)
NZ (1) NZ728636A (es)
PE (1) PE20170464A1 (es)
PH (1) PH12017500493A1 (es)
SG (1) SG11201701330PA (es)
SV (1) SV2017005389A (es)
TN (1) TN2017000072A1 (es)
TW (1) TWI599358B (es)
WO (1) WO2016043997A1 (es)
ZA (1) ZA201700826B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR107893A1 (es) * 2016-03-15 2018-06-28 Astrazeneca Ab TERAPIAS COMBINADAS, COMBINACIÓN DE UN INHIBIDOR DE BACE Y UN ANTICUERPO O UN FRAGMENTO DE UNIÓN AL ANTÍGENO PARA EL TRATAMIENTO DE UN TRASTORNO ASOCIADO CON LA ACUMULACIÓN DE b AMILOIDE
TWI735600B (zh) * 2016-07-01 2021-08-11 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途
US10034861B2 (en) 2016-07-04 2018-07-31 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
JP2019530647A (ja) 2016-08-18 2019-10-24 イーライ リリー アンド カンパニー Ｂａｃｅ−１阻害剤と抗ｎ３ｐｇｌｕ ａベータ抗体の併用療法
TWI669119B (zh) * 2016-10-21 2019-08-21 美國禮來大藥廠 組合療法
BR112018013084A2 (pt) 2016-10-28 2018-12-11 H Lundbeck As tratamentos de combinação compreendendo a administração de imidazopirazinonas
TWI705975B (zh) * 2017-04-20 2020-10-01 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途
EP3658172A4 (en) 2017-07-25 2021-05-05 TrueBinding, Inc. TREATING CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND HIS LIGAND
AR113926A1 (es) 2017-12-14 2020-07-01 H Lundbeck As Derivados de 1h-pirazolo[4,3-b]piridinas
LT3723807T (lt) 2017-12-14 2021-12-10 H. Lundbeck A/S Kombinuoti gydymai, apimantys 1h-pirazolo[4,3-b]piridinų vartojimą
US11535611B2 (en) 2017-12-20 2022-12-27 H. Lundbeck A/S Pyrazolo[3,4-B]pyridines and imidazo[1,5-B]pyridazines as PDE1 inhibitors
US12350278B2 (en) 2018-06-27 2025-07-08 Joshua O. Atiba Therapy and prevention of prion protein complex infections in non-human animals
US10350226B1 (en) 2018-06-27 2019-07-16 Joshua O. Atiba Therapy and prevention of prion protein complex infections
CN113711036B (zh) 2019-01-30 2025-03-18 真和制药有限公司 抗gal3抗体及其用途
US20230236199A1 (en) * 2020-04-23 2023-07-27 Eli Lilly And Company Subcutaneous absorption and bioavailability of antibodies
CN116157151A (zh) 2020-05-26 2023-05-23 真和制药有限公司 通过阻断半乳凝素-3治疗炎性疾病的方法
CN119497721A (zh) 2022-07-29 2025-02-21 艾莱克特有限责任公司 转铁蛋白受体抗原结合结构域及其用途
JP2025528751A (ja) 2022-07-29 2025-09-02 アレクトル エルエルシー Ｃｄ９８ｈｃ抗原結合ドメイン及びその使用法
WO2025166042A1 (en) 2024-01-31 2025-08-07 Alector Llc Cd98hc antigen-binding domains and uses therefor
WO2025264572A1 (en) 2024-06-17 2025-12-26 Alector Llc Transferrin receptor antigen-binding domains and uses therefor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1660443B1 (en) 2003-08-08 2009-03-04 Schering Corporation Cyclic amine bace-1 inhibitors having a benzamide substituent
ES2548774T3 (es) * 2008-01-18 2015-10-20 Eisai R&D Management Co., Ltd. Derivado de aminodihidrotiazina condensado
DK3339323T3 (da) * 2010-08-12 2020-01-20 Lilly Co Eli Anti-n3pglu-amyloid-beta-peptid-antistoffer og anvendelser deraf
GB201101140D0 (en) 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
TWI593692B (zh) * 2013-03-12 2017-08-01 美國禮來大藥廠 四氫吡咯并噻嗪化合物

Also Published As

Publication number Publication date
TN2017000072A1 (en) 2018-07-04
JP2017529348A (ja) 2017-10-05
US9999624B2 (en) 2018-06-19
ZA201700826B (en) 2018-12-19
IL250387A0 (en) 2017-03-30
AU2015318257B2 (en) 2018-06-14
CR20170080A (es) 2017-03-30
CO2017001875A2 (es) 2017-05-19
EA031764B1 (ru) 2019-02-28
JP6339741B2 (ja) 2018-06-06
SV2017005389A (es) 2018-01-17
PE20170464A1 (es) 2017-04-26
WO2016043997A1 (en) 2016-03-24
TW201618786A (zh) 2016-06-01
US20170224702A1 (en) 2017-08-10
AP2017009794A0 (en) 2017-03-31
PH12017500493A1 (en) 2017-08-07
SG11201701330PA (en) 2017-04-27
CN106687136A (zh) 2017-05-17
EP3193882A1 (en) 2017-07-26
KR20170036103A (ko) 2017-03-31
ECSP17015977A (es) 2018-03-31
AU2015318257A1 (en) 2017-02-16
TWI599358B (zh) 2017-09-21
MX2017003414A (es) 2017-06-19
DOP2017000071A (es) 2017-06-15
EA201790305A1 (ru) 2017-07-31
BR112017003571A2 (pt) 2017-12-19
KR101871128B1 (ko) 2018-06-25
NZ728636A (en) 2018-05-25
AR101740A1 (es) 2017-01-11
CA2956835A1 (en) 2016-03-24

Similar Documents

Publication Publication Date Title
SV2017005389A (es) Terapia combinada
CL2017000285A1 (es) Terapia combinada para el tratamiento de un paramixovirus
IL277215A (en) Use of anti-IL-36R antibodies to treat generalized purulent urticaria
CL2017000335A1 (es) Tratamientos conjuntos con anticuerpos anti cd40
BR112016019871A2 (pt) anticorpos anti-cd38 para o tratamento de leucemia linfoblástica aguda
BR112018014016A2 (pt) combinação de um agonista de ox40 e um agonista de anticorpo monoclonal 4-1bb para tratamento de câncer
EA201990296A1 (ru) Антитела против siglec-7 для лечения рака
MX2016002826A (es) Anticuerpos anti-b7-h1 para tratar tumores.
CL2016001979A1 (es) Métodos de tratamiento de enfermedad de alzheimer.
PT2976360T (pt) Terapia envolvendo anticorpos contra claudina 18.2 para o tratamento de cancro
EA201790569A1 (ru) Антитела и иммуноконъюгаты против cll-1
PT2958945T (pt) Terapia de combinação envolvendo anticorpos contra claudina 18.2 para tratamento de cancro
HUE053239T2 (hu) Humanizált tau-ellenanyagok Alzheimer-kór kezelésére
MX2018008105A (es) Compuestos inhibidores de metaloenzima.
MX2019011423A (es) Metodos de tratamiento de enfermedades neurodegenerativas.
MX2018012493A (es) Métodos para controlar y tratar el cáncer.
CL2017002983A1 (es) Terapia combinada de un anticuerpo anti-cd-20 con un inhibidor de bcl-2 y un inhibidor de mdm2
UY36406A (es) 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139
MX382904B (es) Combinaciones de fármacos para tratar mieloma múltiple.
IL287832A (en) Methods of administering anti-cd38 antibody to treat multiple myeloma
CY1122784T1 (el) Αλογονωμενες κιναζολιν-τηf-αμινες ως αναστολεις του ρdε1
JOP20190190B1 (ar) معالجة سرطان
MX2017011272A (es) Metodo de tratamiento para la colangitis esclerosante primaria.
CL2019003485A1 (es) Métodos para redicur la proteinuria en un sujeto humano que padece de nefropatía por inmunoglobulina a. (divisional solicitud 201900909)
PT3463328T (pt) Seladelpar para o tratamento de colangite biliar primária